137 related articles for article (PubMed ID: 25977837)
1. Lessons Learned and Potentials for Improvement in CNS Drug Development: ISCTM Section on Designing the Right Series of Experiments.
Szabo ST; Kinon BJ; Brannan SK; Krystal AK; van Gerven JM; Mahableshwarkar A; Sachs GS
Innov Clin Neurosci; 2015; 12(3-4):11S-25S. PubMed ID: 25977837
[TBL] [Abstract][Full Text] [Related]
2. The NIMH 'Fast-Fail Trials' (FAST) Initiative: Rationale, Promise, and Progress.
Grabb MC; Hillefors M; Potter WZ
Pharmaceut Med; 2020 Aug; 34(4):233-245. PubMed ID: 32705569
[TBL] [Abstract][Full Text] [Related]
3. Trial designs likely to meet valid long-term Alzheimer's disease progression effects: learning from the past, preparing for the future.
Kemp AS; Grossberg GT; Romano SJ; Arnold DL; Ryan JM; Bullock R; Streiner DL
Int J Alzheimers Dis; 2009 Dec; 2009():. PubMed ID: 20798873
[TBL] [Abstract][Full Text] [Related]
4. Translational and Early Phase Strategies for Treatment Development: Report of ISCTM Autumn 2013 Symposium.
Young JW; Potter WZ; Riley S; Groeneveld GJ; Kinon BJ; Egan MF; Feltner DE
Innov Clin Neurosci; 2015; 12(3-4):5S-10S. PubMed ID: 25977839
[TBL] [Abstract][Full Text] [Related]
5. Developing a clinical translational neuroscience taxonomy for anxiety and mood disorder: protocol for the baseline-follow up Research domain criteria Anxiety and Depression ("RAD") project.
Williams LM; Goldstein-Piekarski AN; Chowdhry N; Grisanzio KA; Haug NA; Samara Z; Etkin A; O'Hara R; Schatzberg AF; Suppes T; Yesavage J
BMC Psychiatry; 2016 Mar; 16():68. PubMed ID: 26980207
[TBL] [Abstract][Full Text] [Related]
6. Trial design and reporting standards for intra-arterial cerebral thrombolysis for acute ischemic stroke.
Higashida RT; Furlan AJ; Roberts H; Tomsick T; Connors B; Barr J; Dillon W; Warach S; Broderick J; Tilley B; Sacks D; ;
Stroke; 2003 Aug; 34(8):e109-37. PubMed ID: 12869717
[TBL] [Abstract][Full Text] [Related]
7. Patient Centricity: Design and Conduct of Clinical Trials in Orphan Diseases: Third of Three Sets of Expanded Proceedings from the 2020 ISCTM Autumn Conference on Pediatric Drug Development.
Busner J; Pandina G; Day S; Mahableshwarkar A; Kempf L; Sheean M; Dunn J
Innov Clin Neurosci; 2023; 20(1-3):25-31. PubMed ID: 37122576
[TBL] [Abstract][Full Text] [Related]
8. Implications of Pediatric Initiatives on CNS Drug Development for All Ages-2020 and Beyond: Second of Three Sets of Expanded Proceedings from the 2020 ISCTM Autumn Conference on Pediatric Drug Development.
Pandina G; Busner J; Horrigan JP; McSherry C; Bateman-House A; Pani L; Kando J
Innov Clin Neurosci; 2023; 20(1-3):18-24. PubMed ID: 37122578
[TBL] [Abstract][Full Text] [Related]
9. Clinician- and Patient-reported Endpoints in CNS Orphan Drug Clinical Trials: ISCTM Position Paper on Best Practices for Endpoint Selection, Validation, Training, and Standardization.
Busner J; Pandina G; Domingo S; Berger AK; Acosta MT; Fisseha N; Horrigan J; Ivkovic J; Jacobson W; Revicki D; Villalta-Gil V
Innov Clin Neurosci; 2021; 18(10-12):15-22. PubMed ID: 35096477
[TBL] [Abstract][Full Text] [Related]
10. From the History of the Croatian Dermatovenereological Society - The Croatian Medical Association and an Overview of Important Information Regarding the Journal Acta Dermatovenerologica Croatica.
Dobrić I
Acta Dermatovenerol Croat; 2018 Dec; 26(4):344-348. PubMed ID: 30665489
[TBL] [Abstract][Full Text] [Related]
11. Innovative Approaches for Slowing Disease Progression in Parkinson's Disease: Takeaways from the 14th Annual International Society for Central Nervous System Clinical Trials and Methodology Scientific Meeting.
Javidnia M; Frasier M; Shoulson I; Turkoz I; Budur K
Innov Clin Neurosci; 2020 Jan; 17(1-3):14-19. PubMed ID: 32547841
[TBL] [Abstract][Full Text] [Related]
12. Outcomes Assessment in Clinical Trials of Alzheimer's Disease and its Precursors: Readying for Short-term and Long-term Clinical Trial Needs.
Posner H; Curiel R; Edgar C; Hendrix S; Liu E; Loewenstein DA; Morrison G; Shinobu L; Wesnes K; Harvey PD
Innov Clin Neurosci; 2017; 14(1-2):22-29. PubMed ID: 28386518
[TBL] [Abstract][Full Text] [Related]
13. The effectiveness of internet-based e-learning on clinician behavior and patient outcomes: a systematic review protocol.
Sinclair P; Kable A; Levett-Jones T
JBI Database System Rev Implement Rep; 2015 Jan; 13(1):52-64. PubMed ID: 26447007
[TBL] [Abstract][Full Text] [Related]
14. Right care, first time: a highly personalised and measurement-based care model to manage youth mental health.
Hickie IB; Scott EM; Cross SP; Iorfino F; Davenport TA; Guastella AJ; Naismith SL; Carpenter JS; Rohleder C; Crouse JJ; Hermens DF; Koethe D; Markus Leweke F; Tickell AM; Sawrikar V; Scott J
Med J Aust; 2019 Nov; 211 Suppl 9():S3-S46. PubMed ID: 31679171
[TBL] [Abstract][Full Text] [Related]
15. ECNP consensus meeting. Bipolar depression. Nice, March 2007.
Goodwin GM; Anderson I; Arango C; Bowden CL; Henry C; Mitchell PB; Nolen WA; Vieta E; Wittchen HU
Eur Neuropsychopharmacol; 2008 Jul; 18(7):535-49. PubMed ID: 18501566
[TBL] [Abstract][Full Text] [Related]
16. Phase 3 DREAM-HF Trial of Mesenchymal Precursor Cells in Chronic Heart Failure.
Borow KM; Yaroshinsky A; Greenberg B; Perin EC
Circ Res; 2019 Jul; 125(3):265-281. PubMed ID: 31318648
[TBL] [Abstract][Full Text] [Related]
17. Special Challenges in Pediatric Drug Development: First of Three Sets of Expanded Proceedings from the ISCTM Autumn Conference on Pediatric Drug Development.
Harvey PD; Busner J; Pandina G; Taylor HG; Grabb M; Jimenez-Shahed J
Innov Clin Neurosci; 2023; 20(1-3):13-17. PubMed ID: 37122579
[TBL] [Abstract][Full Text] [Related]
18. Assessing cognitive function in bipolar disorder: challenges and recommendations for clinical trial design.
Burdick KE; Ketter TA; Goldberg JF; Calabrese JR
J Clin Psychiatry; 2015 Mar; 76(3):e342-50. PubMed ID: 25830456
[TBL] [Abstract][Full Text] [Related]
19. CNS Drug Development, Lessons Learned, Part 4: The Role of Brain Circuitry and Genes-Tasimelteon as an Example.
Preskorn SH
J Psychiatr Pract; 2017 Nov; 23(6):425-430. PubMed ID: 29303950
[TBL] [Abstract][Full Text] [Related]
20. Taking Personalized Medicine Seriously: Biomarker Approaches in Phase IIb/III Studies in Major Depression and Schizophrenia.
Murck H; Laughren T; Lamers F; Picard R; Walther S; Goff D; Sainati S
Innov Clin Neurosci; 2015; 12(3-4):26S-40S. PubMed ID: 25977838
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
